Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.4900 (2.93%) ($9.4900 - $9.4900) on Thu. Mar. 24, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.34% (three month average) | RSI | 70 | Latest Price | $9.4900(2.93%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.6% a day on average for past five trading days. | Weekly Trend | FOLD advances 6.1% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(64%) IWO(52%) IWC(48%) IWM(48%) XBI(45%) | Factors Impacting FOLD price | FOLD will decline at least -2.17% in a week (0% probabilities). VIXM(-27%) VXX(-12%) UUP(-11%) UNG(-9%) USO(-2%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.17% (StdDev 4.34%) | Hourly BBV | -0.1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $9.62(-1.35%) | 10 Day Moving Average | $9.44(0.53%) | 20 Day Moving Average | $8.92(6.39%) | To recent high | -23.8% | To recent low | 20.4% | Market Cap | $2.451b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |